News

Takeda Reports Adcetris Combo Approved by EC for Hodgkin Lymphoma
Takeda Pharmaceutical Company Limited (NYSE: TAK )’s ADCETRIS® (brentuximab vedotin) in combination with ECADD was authorized ...
PMLive19h
Takeda receives EC approval for Adcetris combination in Hodgkin lymphoma
The drug has been approved in combination with the chemotherapy regimen etoposide, cyclophosphamide, doxorubicin, dacarbazine ...
The Pharma Letter19h
Takeda wins new EC approval for Adcetris
The European Commission (EC) has approved Adcetris (brentuximab vedotin) in combination with etoposide, cyclophosphamide, ...
GlobalData on MSN21h
EC approves Takeda ADC plus chemo for stage IIb Hodgkin’s lymphoma
The European Commission (EC) has approved Takeda's antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) plus the ...